The study introduces
BAY 1436032, a newly developed inhibitor specifically targeting the mutant form of
isocitrate dehydrogenase 1 (mIDH1), which is often found in various types of
cancer. This enzyme, when mutated, leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG), which is implicated in cancer progression by disrupting cellular differentiation and causing hypermethylation of histones and DNA.
The research details the optimization process that identified BAY 1436032 as a candidate for treating mIDH1-dependent cancers. The inhibitor demonstrated high selectivity and potency against multiple IDH1-R132X mutant variants in vitro, effectively reducing 2-HG levels in both patient-derived and engineered cell lines. The compound also induced differentiation and maturation in mIDH1 tumor cells at nanomolar concentrations.
Furthermore, the study highlights the in vivo efficacy of BAY 1436032 in
glioma and
intrahepatic cholangiocarcinoma tumor models, with a focus on 2-HG levels as a potential biomarker. The compound's ability to penetrate the blood-brain barrier was supported by preclinical data.
The conclusion of the research underscores the potential of BAY 1436032 as a potent and selective inhibitor of mIDH1, with a Phase I clinical trial being planned to evaluate its safety, pharmacokinetics, and anti-tumor effects in
solid tumor patients. The findings were presented at the 107th Annual Meeting of the American Association for Cancer Research, with the abstract published in the Cancer Research journal.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
